Biopharmaceutics classification system (BCS) class IV compounds, exhibits low solubility, intestinal permeability and oral bioavailability among all the pharmaceutical class of drugs. Therefore, these drugs need a more compatible and efficient delivery system. Since, their solubility in various mediums will remains a limitation. Hence, the mesoporous Nanomatrix approach may prove to be a suitable solution ahead. Therefore, in the present study, the polymer-coated mesoporous material like Sylysia 350, Carbon, Tin Oxide are opted for the BCS class IV drug like Apixaban to attain higher solubility and dissolution.  The prepared Nanomatrix was evaluated for its particle size, DSC, Solubility and dissolution studies. For this study, Apixaban was opted for formulating Sylysia 350, Carbon, Tin Oxide based Mesoporous Nanomatrix system. Nanomatrix was prepared by the Amorphous solid dispersion method using probe sonication. The mesoporous Nanomatrix of Apixaban showed improvement in the solubility in water by approx.7 folds when Apixaban used in combination with Sylysia 350 and Polymer HPMC K15M.  From the present study, we can conclude that the optimized Apixaban mesoporous Nanomatrix may prove to be a suitable potential option for solubility enhancement, increase in-vitro drug release and effective delivery of BCS class IV drugs.

The nanocochleates are mainly prepared from the liposomes of active pharmaceutical ingredients (APIs) with the help of inactive ingredients like phosphatidylserine (PS) and calcium. The PS shows a considerable binding affinity towards calcium mainly due to the calcium’s tendency to lose part of its hydration shell and to displace water upon complexation. Due to neutralization of the electrostatic charge, calcium causes aggregation & fusion of liposomes composed PS with each other. It has been reported that ca++ has an affinity to form a more tightly packed & highly ordered and less hydrated structure than mg++ with phosphatidylserine, even at a much lower concentration. It is well documented that ca++ plays a vital role in natural membrane fusion phenomena while other cations are ineffective in most such systems. The stability of Nano-cochleate can be increased by doing freeze-drying of finished product which in turn provides a longer shelf life to the product at, where solution form is most unstable. Based on various literature survey and laboratory work, ‘The Ethanol Injection Method’ was selected for the preparation of Nanoliposomes followed by Nanocochleates. For this study; Paclitaxel was selected as an Active Pharmaceutical Ingredient (API) to formulate Phospholipid based Nanocochleate. The developed Nanocochleates exhibited higher encapsulation efficiency and controlled release of Paclitaxel. This technology may bring about a reduction in dose as well as cost and increase patient compliance. These Nanocochleates could therefore advantageously be employed to improve anticancer activity of Paclitaxel and an alternative to present intravenous administration. From the present study, it can be concluded that the developed Nanocochleates exhibited higher encapsulation efficiency and controlled release of Paclitaxel which may prove to be a suitable & potential candidate for healing a Cancer at a lower concentration.